One day this type of process will be utilized to create allogenic completely safe preventative cancer vaccines which the library of antigen targets that UCLA and others have will be used for.
From this: ''Stephen A. Johnston, cofounder of the health-care start-up Calviri and a scientist at Arizona State University’s Biodesign Institute, has a lot of experience telling people that such a vaccine is possible. The response he usually gets—especially from immunologists and cancer biologists—is a sardonic chuckle, if not a blatant eye roll. But Johnston is betting that he’ll get the last laugh. He is currently testing a preventive cancer vaccine, which induces an immune response to peptides produced from mutated messenger RNA (mRNA), in a $6 million, 5-year study in dogs. The study, called the Vaccination Against Canine Cancer Study, or VACCS, is the largest, most expensive interventional veterinary cancer trial to date.
Although testing cancer therapies in dogs is still unusual in cancer research, the practice is growing as scientists realize that our canine friends provide a much better preclinical model than mice. “If we show that [the vaccine] is successful in dogs, it’s really hard to argue why you wouldn’t try to do this in people,” Johnston says.'' https://cen.acs.org/biological-chemistry/cancer/Preventive-cancer-vaccine-based-neoantigens/99/i37